AZITHROMYCIN | N050809 | TEVA PARENTERAL MEDICINES INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 3 | Active | Tampere University | 1,320 | 2003-12 → 2027-12-31 | |
| Phase 3 | Active | Barcelona Institute for Global Health | 20,560 | 2021-03-15 → 2026-04-30 | |
| Phase 4 | Active | University of California, San Francisco | 320,000 | 2022-02-07 → 2028-03-01 | |
| Phase 2 | Active | Massachusetts General Hospital | 920 | 2021-10-31 → 2026-05-31 | |
| Phase 1/2 | Active | Vanderbilt University Medical Center | 64 | 2017-08-19 → 2026-12-30 | |
| Phase 4 | Active | University of Oxford | 177 | 2017-10-15 → 2028-10 | |
| Phase 4 | Active | University of Maryland, Baltimore | 99,700 | 2020-09-24 → 2026-03-31 | |
| Phase 2 | Active | Copenhagen Studies on Asthma in Childhood | 70 | 2010-11 → 2033-10 | |
| Phase 4 | Recruiting | University Hospital, Montpellier | 72 | 2023-02-03 → 2026-02 | |
| Phase 3 | Recruiting | Centre Hospitalier Universitaire, Amiens | 424 | 2018-02-05 → 2029-02-05 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
16 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Dec 28, 2006 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.